Abstract
A mechanistic model was developed with the objective to characterize weight gain and essential amino acid (EAA) deposition in the different tissue pools that make up the pregnant sow: placenta, allantoic fluid, amniotic fluid, fetus, uterus, mammary gland, and maternal body were considered. The data used in this modelling approach were obtained from published scientific articles reporting weights, crude protein (CP), and EAA composition in the previously mentioned tissues; studies reporting not less than 5 datapoints across gestation were considered. A total of 12 scientific articles published between 1977 and 2020 were selected for the development of the model and the model was validated using 11 separate scientific papers. The model consists of three connected sub-models: protein deposition (Pd) model, weight gain model, and EAA deposition model. Weight gain, Pd, and EAA deposition curves were developed with nonparametric statistics using splines regression. The validation of the model showed a strong agreement between observed and predicted growth (r2 = 0.92, root mean square error = 3%). The proposed model also offered descriptive insights into the weight gain and Pd during gestation. The model suggests that the definition of time-dependent Pd is more accurately described as an increase in fluid deposition during mid-gestation coinciding with a reduction in Pd. In addition, due to differences in CP composition between pregnancy-related tissues and maternal body, Pd by itself may not be the best measurement criteria for the estimation of EAA requirement in pregnant sows. The proposed model also captures the negative maternal Pd that occurs in late gestation and indicates that litter size influences maternal tissue mobilization more than parity. The model predicts that the EAA requirements in early and mid-gestation are 75, 55 and 50% lower for primiparous sows than parity 2, 3 and 4+ sows, respectively, which suggest the potential benefits of parity segregated feeding.
Development, evaluation and use of COVID‐19 vaccines in older adults: Preliminary principles for the pandemic and beyond
